AspenBio Pharma to Present at the Canaccord Adams 29th Annual Global Growth Conference
* Reuters is not responsible for the content in this press release.
CASTLE ROCK, CO, Jul 30 (MARKET WIRE) --
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company
dedicated to the development of novel diagnostics and drugs for humans
and animals, has been invited to present at the Canaccord Adams 29th
Annual Global Growth Conference. The conference will be held at the
InterContinental Boston on August 11-13, 2009.
Company management is scheduled to present on Tuesday, August 11, 2009 at
8:00 a.m. Eastern Time with one-on-one meetings held throughout the day.
Management will discuss the company's progress including its recently
filed Premarket Notification [510(k)] with the U.S. Food and Drug
Administration for its AppyScore Test, the first blood-based test
designed as an aid in the diagnosis of human appendicitis.
For more information about the conference or to schedule a one-on-one
meeting with the company, contact your Canaccord Adams institutional sales
representative.
About Canaccord Adams, Inc.
Canaccord Adams is a leading independent financial services firm committed
to fostering the entrepreneurial economy by bringing corporate and
institutional clients a unique perspective on global investment
opportunities. With operations in research, sales and trading, and
investment banking, its 225 professionals seek out emerging opportunities
in key sectors -- mining and metals, energy, technology, life sciences,
consumer, real estate, sustainability and infrastructure. Located in ten
offices internationally, its experienced team generates focused,
actionable ideas that identify opportunity and facilitate growth.
Canaccord Adams, the international capital markets division of Canaccord
Capital Inc., has operations in Toronto, London, Boston, Vancouver, New
York, Calgary, San Francisco, and Houston. More information is available
at www.canaccordadams.com.
About AspenBio Pharma, Inc.
AspenBio Pharma's mission is to be a leader in the development and
commercialization of innovative products that address unmet diagnostic and
therapeutic needs in both Human and Animal Health. Our Human Health
Division is addressing the difficult challenge of diagnosing appendicitis
in the hospital emergency department setting. Our Animal Health Division
is focused on therapeutic proteins that support reproductive efficiency in
non-companion animals of economic importance. For more information, go to
www.aspenbiopharma.com.
Company Contact:
Gregory Pusey
Vice Chairman
Tel 303-722-4008
Investor Relations:
Liolios Group, Inc.
Email Contact
Ron Both or Geoffrey Plank
Tel 949-574-3860
Copyright 2009, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters